RESEARCH 研究の報告

2024.2.1

Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.

著者 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Kawasaki T, Kobayashi K, Imai H, Kagamu H.

Int J Clin Oncol. 2024 Feb;29(2):124-133. doi: 10.1007/s10147-023-02445-4. Epub 2023 Dec 31.

PMID: 38160406

2024.1.19

Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.

著者 Ito K, Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Imai H, Kuji I, Kagamu H.

Oncol Lett. 2024 Jan 19;27(3):110. doi: 10.3892/ol.2024.14243. eCollection 2024 Mar.

PMID: 38304175 Free PMC article.

2024.1.10

Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.

著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T.

Cancers (Basel). 2024 Jan 10;16(2):301. doi: 10.3390/cancers16020301.

PMID: 38254791; PMCID: PMC10814048.

2023.12.2

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor- Mutated Advanced Non-Small-Cell Lung Cancer.

著者 Jänne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, Laktionov K, Yang TY, Yu Y, Kato T, Jiang L, Chewaskulyong B, Lucien Geater S, Maurel JM, Rojas C, Takahashi T, Havel L, Shepherd FA, Tanaka K, Ghiorghiu D, Amin NP, Armenteros-Monterroso E, Huang X, Chaudhry AA, Yang JC.

J Clin Oncol. 2024 Mar 1;42(7):808-820. doi: 10.1200/JCO.23.02219. Epub 2023 Dec 2.

PMID: 38042525; PMCID: PMC10906563.

2023.11.27

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.

著者 Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K.

Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5.

PMID: 38012343 Free PMC article.

2023.11.8

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

著者 Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators.

N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.

PMID: 37937763.

2023.9.19

Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.

著者 Yamaguchi O, Kaira K, Imai H, Mouri A, Shiono A, Miura Y, Hashimoto K, Kobayashi K, Kagamu H.

Oncology. 2024;102(3):271-282. doi: 10.1159/000534169. Epub 2023 Sep 19.

PMID: 37725914

2023.8.22

Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib

著者 Kaira K, Imai H, Mouri A, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Kobayashi K, Kawasaki T, Yasuda M, Kagamu H.

Thorac Cancer. 2023 Oct;14(29):2950-2961. doi: 10.1111/1759-7714.15082. Epub 2023 Aug 22.

PMID: 37605832 Free PMC article.

2023.8.18

Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.

著者 Nishihara-Kato F, Imai H, Tsuda T, Wasamoto S, Nagai Y, Kishikawa T, Miura Y, Ono A, Yamada Y, Masubuchi K, Osaki T, Nakagawa J, Umeda Y, Minemura H, Kozu Y, Taniguchi H, Ohta H, Kaira K, Kagamu H.

Oncology. 2024;102(1):30-42. doi: 10.1159/000533604. Epub 2023 Aug 18.

PMID: 37598676

2023.8.29

Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed

著者 Hisao Imai,　Satoshi Wasamoto,　Takeshi Tsuda,　Yoshiaki Nagai,　Takayuki Kishikawa,　Ken Masubuchi,　Takashi Osaki,　Yosuke Miura,　Yukihiro Umeda,　Akihiro Ono,　Hiroyuki Minemura,　Yutaka Yamada,　Junichi Nakagawa,　Yuki Kozu,　Hirokazu Taniguchi,　Hiromitsu Ohta,　Takashi Kasai,　Kyoichi Kaira,　Hiroshi Kagamu.

Thorac Cancer . 2023 Sep;14(25):2567-2578. doi: 10.1111/1759-7714.15036. Epub 2023 Jul 19.

PMID: 37469246 PMCID: PMC10481141 DOI: 10.1111/1759-7714.15036

2023.5.8

Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma.

著者 Ito K,　Yamaguchi O,　Kaira K,　Imai H,　Kagamu H.

Lung Cancer . 2023 May:179:107193. doi: 10.1016/j.lungcan.2023.107193. Epub 2023 Apr 10.

PMID: 37058785 DOI: 10.1016/j.lungcan.2023.107193

2023.5.3

Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.

著者 Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K.

Cancer Sci. 2023 Aug;114(8):3342-3351. doi: 10.1111/cas.15831. Epub 2023 May 3.

PMID: 37139543; PMCID: PMC10394136.